Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01585636 · ClinicalTrials.gov registry record · Phase 1
Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers
A Phase 1 study of Tuberculosis, sponsored by Sequella.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT01585636 is a Phase 1 study of Tuberculosis that has completed, run by Sequella. The registered enrollment target is 62 participants, below the 932-participant average among 29 other Tuberculosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01585636, a Phase 1 study of Tuberculosis, has completed, sponsored by Sequella.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 1, "first in man" study to evaluate single oral doses (5-300 mg) of SQ109, a new investigational drug being developed for treatment of tuberculosis. If single doses are safe and well tolerated, subsequent studies will evaluate multiple daily doses in healthy volunteers and patients with pulmonary tuberculosis.
Conditions Studied
Interventions
- DRUG SQ109
Study Locations (1)
Kansas
- Quintiles Phaes 1 Clinical Study Unit - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01585636
The ClinicalTrials.gov registry entry for NCT01585636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 932-participant average among 29 other Tuberculosis trials with a reported enrollment target (93% lower). The listed sponsor is Sequella, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tuberculosis appearing as the primary indexed condition, and to 1 intervention - of which SQ109 is the first listed.
NCT01585636 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT01585636 about?
NCT01585636 is a clinical study titled "Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers". This is a phase 1, "first in man" study to evaluate single oral doses (5-300 mg) of SQ109, a new investigational drug being developed for treatment of tuberculosis. If single doses are safe and well tolerated, subsequent studies will evaluate multiple daily doses in healthy volunteers and patients w...
What is the current status of trial NCT01585636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2006-09. Estimated completion is 2007-02.
What conditions does trial NCT01585636 study?
This clinical trial studies the following conditions: Tuberculosis.
What interventions are being tested in trial NCT01585636?
The interventions under investigation include: SQ109 (DRUG).
Who is sponsoring clinical trial NCT01585636?
This trial is sponsored by Sequella, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01585636 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tuberculosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin
COMPLETED · Phase 1
-
Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers
COMPLETED · Phase 1
-
Phase I Trial of DAR-901
COMPLETED · Phase 1
-
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
COMPLETED · Phase 1
-
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
COMPLETED · Phase 1
-
Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.